[Establishment of a model for evaluating hypolipidemic effect in HepG2 cells]

Wei Sheng Yan Jiu. 2010 Mar;39(2):155-8.
[Article in Chinese]

Abstract

Objective: To establish a model of evaluating hypolipidemic effect in vitro.

Methods: Adding cholesterol to the culture medium for HepG2 cells to induce a hypercholesterolemia model. The content of cellular cholesterol and the expression of protein regulating cholesterol metabolism in HepG2 cells were determined. The validation of the model was identified by lovastatin, a widely used cholesterol-lowering drug. Free fatty acid was added to the culture medium for HepG2 cells to induce a hypertriglyceridemia model. The content of cellular triglyceride and the absorption rate of free fatty acid were determined. The validation of the model was identified by fenofibrate, a triglyceride-lowering drug.

Results: Cellular cholesterol content was increased and the expression of HMG-CoA redutase, SREBP-2 and LDLR were decreased after adding cholesterol and 25-hydrocholesterol to the culture medium. Cellular cholesterol was decreased and the expression of SREBP-2 and LDLR were up-regulated by Lovastatin. The absorption of oleic acid in cells was up to 40% after adding oleic acid (50 micromol) to the culture medium for 6 h. The absorption of free fatty acid was increased but the content of cellular triglyceride was not increased in cells by Fenofibrate.

Conclusion: This model might be an effective method for screening and assessing functional factors for lowing plasma lipids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Cholesterol / metabolism*
  • Culture Media / chemistry
  • Drug Evaluation
  • Hep G2 Cells
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / metabolism
  • Hypolipidemic Agents / pharmacology*
  • Lovastatin / pharmacology
  • Models, Biological*
  • Receptors, LDL / metabolism
  • Sterol Regulatory Element Binding Protein 2 / metabolism
  • Triglycerides / metabolism*

Substances

  • Culture Media
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Receptors, LDL
  • SREBF2 protein, human
  • Sterol Regulatory Element Binding Protein 2
  • Triglycerides
  • Cholesterol
  • Lovastatin